Department of Oral Implantology and Prosthetic Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), Universiteit van Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Department of Plastic and Reconstructive, Hand, and Aesthetic Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
J Biomed Mater Res A. 2018 Sep;106(9):2363-2371. doi: 10.1002/jbm.a.36398.
Biomimetically deposited calcium phosphate-based coatings of prostheses can serve as a vehicle for the targeted delivery of growth factors to the local implant environment. Based on indirect evidence in previous studies we hypothesize that such agents are liberated gradually from the coating via a cell-mediated degradation. In the present study, we tested this hypothesis by investigating the release mechanism and its kinetics by use of a radiolabeled osteogenic agent ( I-BMP-2) under conditions in which native cell populations with a coating-degradative potential were either absent or present. The release of I-BMP-2 was monitored for 5 weeks, either in vitro or after implantation at an ectopic (subcutaneous) site in rats in vivo. Only from implants that bore a coating-incorporated depot of bone morphogenetic protein 2 (BMP-2) was the agent released slowly and steadily over 5 weeks, that is, 50% of the loaded dose was liberated in vivo (5 to 10% weekly), as against 14.6% in vitro (less than 1% weekly). The coatings bearing an incorporated depot of BMP-2 underwent significant cell-mediated degradation, whereas under cell-free conditions no degradation occurred, and the spontaneous release of BMP-2 was negligible. Our findings confirm this carrier system to be a suitable vehicle for the sustained and cell-mediated delivery of BMP-2. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A:2363-2371, 2018.
仿生沉积的钙磷基涂层可作为一种载体,将生长因子靶向递送到局部植入环境中。基于之前研究中的间接证据,我们假设这些药物通过细胞介导的降解作用逐渐从涂层中释放出来。在本研究中,我们通过使用放射性标记的成骨剂( I-BMP-2)在存在或不存在具有涂层降解潜力的天然细胞群的情况下,研究了释放机制及其动力学,从而验证了这一假设。在体外或在异位(皮下)部位植入大鼠体内后,我们监测了 5 周内 I-BMP-2 的释放情况。只有在带有骨形态发生蛋白 2(BMP-2)涂层库的植入物中,该药物才能在 5 周内缓慢而稳定地释放,即 50%的加载剂量在体内释放(每周 5%至 10%),而在体外则为 14.6%(每周不到 1%)。带有 BMP-2 涂层库的涂层经历了明显的细胞介导的降解,而在无细胞条件下则不会发生降解,BMP-2 的自发释放可以忽略不计。我们的研究结果证实了这种载体系统是一种合适的载体,可用于持续和细胞介导的 BMP-2 递药。 © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A:106A:2363-2371,2018。